Why Hims & Hers Health (HIMS) Stock Is Up Today

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration with drugmaker Novo Nordisk to sell its popular GLP-1 weight-loss drugs, which also resolved a recent legal dispute. 

The deal marked a surprising turn, as Novo Nordisk had been in a legal battle with Hims & Hers over the sale of compounded versions of its blockbuster drugs. As part of the new partnership, Hims & Hers gained the ability to offer FDA-approved medications like Ozempic and Wegovy directly on its platform. 

In return, the company planned to limit its offering of compounded semaglutide and stop advertising those products. 

Following the announcement, Novo Nordisk dismissed its lawsuit against the company, signaling an end to their feud. The agreement was viewed as a strategic shift for Hims & Hers, moving it from a market disruptor to a more established healthcare provider.

Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 77 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 10 days ago when the stock dropped 5.9% on the news that a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 

The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.

Hims & Hers Health is down 35.9% since the beginning of the year, and at $21.43 per share, it is trading 67.6% below its 52-week high of $66.18 from July 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $1,578.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.